Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 2054 results found since Jan 2013.

HAND2 is a novel obesity-linked adipogenic transcription factor regulated by glucocorticoid signalling
Conclusions/interpretationIn summary, our study identifies HAND2 as a novel obesity-linked adipocyte transcription factor, highlighting new mechanisms of GR-dependent adipogenesis in humans and mice.Data availabilityArray data have been submitted to the GEO database at NCBI (GSE148699).Graphical abstract
Source: Diabetologia - August 1, 2021 Category: Endocrinology Source Type: research

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
CONCLUSIONS: AIMSS are chronic and complex symptoms with a significant impact on women with early breast cancer taking AI. To date, evidence for safe and effective systemic therapies for prevention or treatment of AIMSS has been minimal. Although this review identified 17 studies with 2034 randomised participants, the review was challenging due to the heterogeneous systemic therapy interventions and study methodologies, and the unavailability of certain trial data. Meta-analysis was thus limited and findings of the review were inconclusive. Further research is recommended into systemic therapy for AIMSS, including high-qua...
Source: Cochrane Database of Systematic Reviews - January 10, 2022 Category: General Medicine Authors: Kate E Roberts India T Adsett Kirsty Rickett Sophie M Conroy Mark D Chatfield Natasha E Woodward Source Type: research

Cancers, Vol. 14, Pages 2380: Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells
In this study, we have investigated how alterations in sphingolipids promote cell survival in ET-resistant breast cancer. We have performed LC-MS-based targeted sphingolipidomics of tamoxifen-sensitive and -resistant MCF-7 breast cancer cell lines. Follow-up studies included treatments of cell lines and patient-derived xenograft organoids (PDxO) with small molecule inhibitors; cytometric analyses to measure cell death, proliferation, and apoptosis; siRNA-mediated knockdown; RT-qPCR and Western blot for gene and protein expression; targeted lipid analysis; and lipid addback experiments. We found that tamoxifen-resistant cel...
Source: Cancers - May 12, 2022 Category: Cancer & Oncology Authors: Purab Pal Alec Millner Svetlana E. Semina Rosemary J. Huggins Logan Running Diana S. Aga Debra A. Tonetti Rachel Schiff Geoffrey L. Greene G. Ekin Atilla-Gokcumen Jonna Frasor Tags: Article Source Type: research

Medical methods for first trimester abortion
CONCLUSIONS: Safe and effective medical abortion methods are available. Combined regimens (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate) may be more effective than single agents (prostaglandin alone or mifepristone alone). In the combined regimen, the dose of mifepristone can probably be lowered to 200 mg without significantly decreasing effectiveness. Vaginal misoprostol is probably more effective than oral administration, and may have fewer side effects than sublingual or buccal. Some results are limited by the small numbers of participants on which they are based. A...
Source: Cochrane Database of Systematic Reviews - May 24, 2022 Category: General Medicine Authors: Jing Zhang Kunyan Zhou Dan Shan Xiaoyan Luo Source Type: research

Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals
Dose Response. 2022 Sep 21;20(3):15593258221120485. doi: 10.1177/15593258221120485. eCollection 2022 Jul-Sep.ABSTRACTPhytochemicals (Pch) present in fruits, vegetables and other foods, are known to inhibit or induce drug metabolism and transport. An exhaustive search was performed in five databases covering from 2000 to 2021. Twenty-one compounds from plants were found to modulate CYP3A and/or P-gp activities and modified the pharmacokinetics and the therapeutic effect of 27 different drugs. Flavonols, flavanones, flavones, stilbenes, diferuloylmethanes, tannins, protoalkaloids, flavans, hyperforin and terpenes, reduce pla...
Source: Dose Response - September 26, 2022 Category: Drugs & Pharmacology Authors: Josefina G ómez-Garduño Renato Le ón-Rodríguez Radam és Alemón-Medina Beatriz E P érez-Guillé Rosa E Soriano-Rosales Ailema Gonz ález-Ortiz Juan L Ch ávez-Pacheco Edelmira Solorio-L ópez Paola Fernandez-P érez Liliana Rivera-Espinosa Source Type: research

Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer
We examined paired tissues from Taiwanese patients and observed that 65.09% and 68.25% of patients exhibited TSTD1 hypomethylation and overexpression, respectively. A significant correlation was found between TSTD1 hypomethylation and overexpression in Taiwanese (74.2%, p = 0.040) and Western (88.0%, p < 0.001) cohorts. High expression of TSTD1 protein was observed in 68.8% of Taiwanese and Korean breast cancer patients. Overexpression of TSTD1 in tumors of breast cancer patients was significantly associated with poor 5-year overall survival (p = 0.021) and poor chemotherapy response (p = 0.008). T47D cells treated with...
Source: Frontiers in Oncology - November 7, 2022 Category: Cancer & Oncology Source Type: research

A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ER α expressing primary and metastatic invasive ductal carcinoma
In conclusion, GART inhibition by LMX or other inhibitors of the de novo purine biosynthetic pathway could be a novel effective strategy for the treatment of primary and metastatic BCs.
Source: Frontiers in Endocrinology - April 18, 2023 Category: Endocrinology Source Type: research

Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
CONCLUSIONS: COS schedules with the additional use of tamoxifen or letrozole are commonly chosen as an alternative regimen in young women with ER positive breast cancer who undergo COS for oocyte or embryo cryopreservation. No randomised controlled trials support the idea that these alternative COS schedules are superior to standard COS. PMID: 24213953 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 8, 2013 Category: Journals (General) Authors: Dahhan T, Balkenende E, van Wely M, Linn S, Goddijn M Tags: Cochrane Database Syst Rev Source Type: research

Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods
CONCLUSIONS Despite the high contraceptive effectiveness of many hormonal and intrauterine reversible contraceptive methods, many HCPs, users and potential users are concerned mainly about side effects and safety of both hormonal and non-hormonal contraceptive methods, and there is scarce information about the many benefits that these methods offer beyond contraception.
Source: Human Reproduction Update - August 11, 2015 Category: OBGYN Authors: Bahamondes, L., Valeria Bahamondes, M., Shulman, L. P. Tags: Reviews Source Type: research

Gynecomastia in Patients with Prostate Cancer: A Systematic Review
Conclusions Bicalutamide-induced gynecomastia and/or mastodynia can effectively be managed by oral tamoxifen (10–20 mg daily) or radiotherapy without relevant side effects. Prophylaxis or therapeutic treatment with tamoxifen results to be more effective than radiotherapy.
Source: PLoS One - August 26, 2015 Category: Biomedical Science Authors: Anders Fagerlund et al. Source Type: research

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
CONCLUSIONS: The LNG-IUS reduces the incidence of benign endometrial polyps and endometrial hyperplasia in women with breast cancer taking tamoxifen. At 12 and 24 months of follow-up, the LNG-IUS increased abnormal vaginal bleeding or spotting among women in the treatment group compared to those in the control. There is no clear evidence from the available randomised controlled trials that the LNG-IUS prevents endometrial cancer in these women. There is no clear evidence from the available randomised controlled trials that the LNG-IUS affects the risk of breast cancer recurrence or breast cancer-related deaths. Larger stud...
Source: Cochrane Database of Systematic Reviews - December 9, 2015 Category: Journals (General) Authors: Dominick S, Hickey M, Chin J, Su HI Tags: Cochrane Database Syst Rev Source Type: research

Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome.
CONCLUSIONS: We found evidence suggesting that clomiphene citrate improves the chance of a clinical pregnancy compared with placebo, but may reduce the chance of live birth or ongoing pregnancy when compared with a gonadotropin. Due to low event rates, we advise caution interpreting these data.The comparison of clomiphene citrate plus medical adjunctive versus clomiphene alone was limited by the number of trials reporting the comparison. The evidence was very low quality and no firm conclusions could be drawn, but very limited evidence suggested a benefit from adjunctive dexamethasone or combined oral contraceptives. Low-q...
Source: Cochrane Database of Systematic Reviews - December 14, 2016 Category: Journals (General) Authors: Brown J, Farquhar C Tags: Cochrane Database Syst Rev Source Type: research

Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review.
CONCLUSIONS: Vaginal testosterone shows preliminary promise as an option to manage sexual side effects of AI therapy in postmenopausal cancer survivors; however, available data are too limited to draw practice-changing conclusions.
. IMPLICATIONS FOR RESEARCH: Large-scale randomized, controlled trials need to be completed to evaluate the efficacy and safety of vaginal testosterone in women taking AIs. PMID: 28635978 [PubMed - in process]
Source: Oncology Nursing Forum - May 1, 2017 Category: Nursing Authors: Lemke EA, Madsen LT, Dains JE Tags: Oncol Nurs Forum Source Type: research